JapanStake
Pharmaceutical · Fiscal year end Mar 31

ZERIA PHARMCEUTICAL CO., LTD.

4559

ゼリア新薬工業株式会社

FIGI BBG000C1WWD34559.T4559 JPCorp. no. 7010001034790

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-07

For the first half of the fiscal year to 2026-03: Revenue ¥40 billion (-5.8% YoY), Ordinary income ¥2.7 billion (-66.6% YoY), Net income ¥1.7 billion (-71.3% YoY).

This periodYear on year
Revenue¥40.0bn-5.8%
Ordinary profit¥2.7bn-66.6%
Net profit to owners¥1.7bn-71.3%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4559/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31
Revenue
¥89.2bn
Net income
¥8.5bn
ROE
8.5%
Equity ratio
60.3%
Dividend / share
¥49
Employees
1,748
Revenue · ¥bn
FY2022: ¥59.5bn 59.5 FY2022FY2023: ¥68.4bn 68.4 FY2023FY2024: ¥75.7bn 75.7 FY2024FY2025: ¥87.3bn 87.3 FY2025FY2026: ¥89.2bn 89.2 FY2026
Net income · ¥bn
FY2022: ¥4.0bn 3.96 FY2022FY2023: ¥6.2bn 6.2 FY2023FY2024: ¥7.7bn 7.73 FY2024FY2025: ¥9.9bn 9.94 FY2025FY2026: ¥8.5bn 8.45 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-03-31¥89.2bn¥8.5bn¥179.7bn¥108.6bn8.5%¥191.8¥10.0bn
2025-03-31¥87.3bn¥9.9bn¥159.2bn¥89.8bn11.7%¥225.42¥12.9bn
2024-03-31¥75.7bn¥7.7bn¥150.5bn¥79.8bn10.7%¥175.39¥12.2bn
2023-03-31¥68.4bn¥6.2bn¥135.0bn¥65.7bn10.3%¥140.26¥13.2bn
2022-03-31¥59.5bn¥4.0bn¥124.3bn¥55.1bn7.1%¥87.76¥9.0bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31
MetricValuePercentile among listed companies
ROE, %8.549.1
Ordinary margin0.123976.6
Equity ratio, %60.358.8
Revenue growth0.021235.1
Net income growth-0.149125.5
Operating cash flow / assets0.055444.1
Policy-uncertainty measure0.66 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Trade & tariffs 1 Regulation 1 Politics & geopolitics 1
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 16.4% held by other listed companies.

Results wording balance: 0.00. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥39.1bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥196m, 2.0% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4559/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Internal control, 2026-06-25: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Segments: Ethical Drug Business, Consumer Health Care Business, Other. /v1/companies/4559/segments
Latest voting result: 2026-06-26 · 剰余金の処分の件 · passed. /v1/companies/4559/voting

Ownership changes

All companies →

Trades by 5% holders

From the 60-day trade tables in 5% reports
¥2,039¥2,130¥2,221 2024-02-022024-05-13 2024-05-13 · bought 588,500 @ ¥2,039 · 有限会社伊部2024-04-01 · sold 200 @ ¥2,130.5 · SMBC日興証券株式会社2024-03-29 · sold 300 @ ¥2,145.1 · SMBC日興証券株式会社2024-03-26 · bought 400 @ ¥2,166 · SMBC日興証券株式会社2024-03-25 · bought 100 @ ¥2,206 · SMBC日興証券株式会社2024-03-19 · sold 200 @ ¥2,197 · SMBC日興証券株式会社2024-03-15 · sold 1,400 @ ¥2,180.9 · SMBC日興証券株式会社2024-03-15 · bought 100 @ ¥2,184 · SMBC日興証券株式会社2024-03-13 · bought 100 @ ¥2,122 · SMBC日興証券株式会社2024-03-12 · sold 16,100 @ ¥2,102 · SMBC日興証券株式会社2024-03-11 · sold 100 @ ¥2,134 · SMBC日興証券株式会社2024-03-11 · bought 100 @ ¥2,134 · SMBC日興証券株式会社2024-03-08 · bought 2,200 @ ¥2,156 · SMBC日興証券株式会社2024-03-04 · sold 600 @ ¥2,149.3 · SMBC日興証券株式会社2024-03-04 · bought 100 @ ¥2,147 · SMBC日興証券株式会社2024-02-29 · sold 400 @ ¥2,113.9 · SMBC日興証券株式会社2024-02-26 · sold 100 @ ¥2,149 · SMBC日興証券株式会社2024-02-26 · bought 200 @ ¥2,149 · SMBC日興証券株式会社2024-02-22 · bought 100 @ ¥2,149 · SMBC日興証券株式会社2024-02-16 · bought 1,900 @ ¥2,166 · SMBC日興証券株式会社2024-02-09 · sold 700 @ ¥2,165 · SMBC日興証券株式会社2024-02-08 · sold 200 @ ¥2,196 · SMBC日興証券株式会社2024-02-07 · sold 500 @ ¥2,211 · SMBC日興証券株式会社2024-02-05 · sold 100 @ ¥2,221.2 · SMBC日興証券株式会社2024-02-02 · bought 2,600 @ ¥2,208.9 · SMBC日興証券株式会社
Bought SoldHover a dot for the trade
HolderPeriodNet sharesNet % of sharesAvg. filed priceRange
有限会社伊部2024-05-13 – 2024-05-13+588,500+1.11pt¥2,039¥2,039–2,039
SMBCファイナンスサービス株式会社2024-04-01 – 2024-04-0100.00pt——
SMBC日興証券株式会社2024-02-02 – 2024-04-01+18,800+0.03pt¥2,133.42¥2,102–2,221
三井住友カード 株式会社2024-04-01 – 2024-04-0100.00pt——

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4559/trades.

5% filings

Large shareholding reports on 4559
FiledFilerStakeChangeStated purpose
2024-07-29Mitsubishi UFJ Financial Group, Inc.6.09%−0.61ptstrategic holding
2024-05-16Ibe13.03%+1.10pt—
2024-04-08Sumitomo Mitsui Banking Corporation4.54%−0.50pt—
2022-09-26Mizuho Bank,Ltd.4.48%−0.57pt—

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
27 issues
Book value
¥9.8bn
Sold in the year
¥174m 1 issues
Bought in the year
— — issues
Mutual, both reports
16
Held by listed cos.
26
HoldsBook valueShares vs. prior yearMutual
ASKA Pharmaceutical Holdings CO., Ltd. 4886¥4,432m0.0%both reports
Mitsubishi HC Capital Inc. 8593¥2,819m0.0%both reports
KINDEN CORPORATION 1944¥2,301m0.0%both reports
株式会社コーセーホールディングス（注）３¥1,897m0.0%stated
MORINAGA MILK INDUSTRY CO.,LTD 2264¥1,700m0.0%both reports
Sumitomo Realty & Development Co.,Ltd. 8830¥1,660m+100.0%—
Mitsubishi UFJ Financial Group, Inc. 8306¥1,391m0.0%no
Yokogawa Bridge Holdings Corp. 5911¥1,251m0.0%no
KISSEI PHARMACEUTICAL CO.,LTD. 4547¥1,245m0.0%both reports
MatsukiyoCocokara & Co 3088¥1,129m0.0%both reports

Held by: MORINAGA MILK INDUSTRY CO.,LTD 2264, KISSEI PHARMACEUTICAL CO.,LTD. 4547, MS&AD Insurance Group Holdings, Inc. 8725, KINDEN CORPORATION 1944, Aichi Financial Group, Inc. 7389, Mebuki Financial Group,Inc. 7167, KOSE Holdings Corporation 4922, ASKA Pharmaceutical Holdings CO., Ltd. 4886, Mitsubishi HC Capital Inc. 8593, DENTSU GROUP INC. 4324, Riken Vitamin Co., Ltd. 4526, YUKI GOSEI KOGYO CO.,LTD. 4531 and 15 more

Purposes, all holdings and mutual flags via /v1/companies/4559/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31
ShareholderSharesRatio
有限会社伊部5,330,00012.09%
日本マスタートラスト信託銀行株式会社（信託口）3,233,0007.34%
株式会社三菱ＵＦＪ銀行2,107,0004.78%
individual holder1,592,0003.61%
森永乳業株式会社1,472,0003.34%
株式会社三井住友銀行1,406,0003.19%
株式会社みずほ銀行1,406,0003.19%
三井住友カード株式会社900,0002.04%
キッセイ薬品工業株式会社867,0001.97%
ゼリア新薬工業従業員持株会766,0001.74%

U.S. funds holding 4559

SEC Form N-PORT, reports to 2026-07-31

45 U.S. funds held 1,834,602 shares worth $24.1m.

FundSharesValue% of fundAs of
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND
VANGUARD STAR FUNDS
445,855$5.8m0.001%2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND
VANGUARD TAX-MANAGED FUNDS
278,718$3.5m0.001%2026-06-30
VANGUARD FTSE ALL-WORLD EX-US SMALL-CAP INDEX FUND
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS
105,940$1.4m0.010%2026-07-31
INTERNATIONAL CORE EQUITY 2 PORTFOLIO
DFA INVESTMENT DIMENSIONS GROUP INC
94,900$1.2m0.003%2026-07-31
THE JAPANESE SMALL COMPANY SERIES
DFA INVESTMENT TRUST CO
86,317$1.1m0.028%2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4559
GET /v1/companies/4559/financials
GET /v1/companies/4559/details
GET /v1/companies/4559/segments
GET /v1/companies/4559/voting
GET /v1/companies/4559/tender-offers
GET /v1/companies/4559/indicators
GET /v1/companies/4559/earnings-releases
GET /v1/events?ticker=4559
GET /v1/companies/4559/trades         
GET /v1/companies/4559/cross-holdings 
GET /v1/companies/4559/brief

Plans from $9 a month · Documentation